Welcome to our dedicated page for Eyenovia SEC filings (Ticker: EYEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Eyenovia’s SEC paperwork can feel as precise—and as daunting—as the microdosed spray that powers its Optejet platform. Between clinical-trial disclosures, patent updates and detailed R&D spend, the company’s 10-K and 10-Q reports often bury the numbers that determine whether a new ophthalmic therapy reaches patients. Stock Titan surfaces those data points instantly, turning 200-page documents into clear takeaways so you can focus on the real question investors ask every quarter: how far is Eyenovia from commercializing its next eye-care breakthrough?
Whether you need the full Eyenovia quarterly earnings report 10-Q filing, an Eyenovia annual report 10-K simplified, or an Eyenovia 8-K material events explained, our platform delivers every form the moment it hits EDGAR. AI-generated highlights reveal trial milestones, cash runway and Optejet licensing revenue, while real-time alerts flag Eyenovia insider trading Form 4 transactions. Looking for management incentives? The latest Eyenovia proxy statement executive compensation is decoded so you understand option grants without reading footnotes.
Here’s how professionals use these insights:
- Track Eyenovia Form 4 insider transactions real-time to spot executive buying or selling before pivotal data releases.
- Compare segment spending with our Eyenovia earnings report filing analysis and gauge burn-rate against trial timelines.
- Save hours understanding Eyenovia SEC documents with AI—from risk factor shifts to pipeline progress.
Stop scrolling through PDFs. Every Eyenovia SEC filings explained simply page blends human expertise with AI so you see the story behind the numbers—fast.
Hyperion DeFi, Inc. will hold its 2025 virtual Annual Meeting on 18 Aug 2025 at 12:00 PM EDT. Stockholders of record as of 18 Jul 2025 will vote on nine items.
- Proposal 1–3: elect five directors, ratify new auditor CBIZ CPAs P.C., and cast a say-on-pay advisory vote.
- Proposal 4: double authorized common stock to 600 million and preferred stock to 60 million. As of 8 Jul 2025 only 244.1 million common and 0.56 million preferred shares remain unissued; the board cites financing flexibility as the main reason.
- Proposal 5: amend the charter to allow stockholders to act by written consent.
- Proposal 6: add 5.3 million shares to the 2018 Omnibus Stock Incentive Plan, raising its pool to 5.73 million shares; just 27,186 shares remain currently.
- Proposal 7: approve issuance of up to 394,236 shares upon warrant exercise under Nasdaq Rule 5635(d).
- Proposal 8: authorize adjournment to solicit more votes if Proposals 4, 5, or 7 lack support.
The proxy discloses a recent auditor transition—Marcum LLP resigned on 2 May 2025 after its attest practice was acquired by CBIZ. Marcum’s 2023–24 reports contained a going-concern paragraph and identified two material weaknesses, which management is addressing.
The charter amendments give the board wide latitude to issue a large number of new shares, potentially introducing dilution risk but also enabling capital raises, M&A and employee incentives. Governance rights improve slightly through the proposed written-consent provision and annual director elections.
Eyenovia, Inc. (Nasdaq: EYEN) has filed a Prospectus Supplement under Form 424B5 to update its existing at-the-market (ATM) equity program with Chardan Capital Markets. The filing registers the offer and sale of up to $14,942,887 in additional common stock, a figure calculated to comply with General Instruction I.B.6 of Form S-3.
• As of 27 June 2025, the company’s non-affiliate public float was approximately $52.8 million, based on 4,853,092 shares at $10.88 per share.
• I.B.6 limits primary offerings to one-third of that float—about $17.6 million—within any 12-month period when the float is under $75 million.
• Eyenovia has already sold $2.66 million of securities during the preceding 12 months, leaving capacity for the newly registered $14.94 million.
The filing does not alter the total $50 million ceiling of the December 30, 2024 amended Sales Agreement, but it refreshes the amount currently eligible for issuance. Shares will be sold from time to time through Chardan acting as sales agent, at market prices on Nasdaq Capital Market under the symbol EYEN.
The supplement reiterates that investment in EYEN entails a high degree of risk and directs investors to previously filed risk factors in the company’s 10-K and 8-K dated 27 June 2025.
FAQ
What is the current stock price of Eyenovia (EYEN)?
What is the market cap of Eyenovia (EYEN)?
